Tiotropium bromide: A review of its use as maintenance therapy in patients with COPD

Treatments in Respiratory Medicine

Volumn 3, Issue 4, 2004, Pages 247-268

  Keam, Susan J ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Anticholinergic bronchodilators; COPD; Health related quality of life; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tiotropium; Tiotropium bromide; Tolerability

Indexed keywords

AMINOPHYLLINE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; FORMOTEROL; GESTODENE; IPRATROPIUM BROMIDE; KETOCONAZOLE; OXITROPIUM BROMIDE; PLACEBO; QUINIDINE; RANITIDINE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BRONCHODILATATION; CANDIDA; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UTILIZATION; DYSPNEA; EPISTAXIS; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HUMAN; INCIDENCE; LUNG FUNCTION; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SINUSITIS; TACHYPHYLAXIS; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 4644353712     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151829-200403040-00005     Document Type: Review

References (94)

1. Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction: a clinicopathological study of patients in London and Chicago. Lancet 1966 Apr 16; 1 (7442): 830-5
2. National Institutes of Health: National Heart Lung and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2003. Executive summary [online]. Available from URL: http://www.goldcopd.com [Accessed 2003 Aug 20]
3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004 Jun 24; 350 (26): 2645-53
4. Sutherland ER, Cherniak RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004 Jun 24; 350 (26): 2689-97
5. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52 (5-6): 521-7
6. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996 Dec; 48 (4): 531-65
7. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000 Feb; 117 (2 Suppl.): 63S-6S
8. Van Noord JA. Tiotropium bromide: a viewpoint by JA van Noord. Drugs 2002; 62 (8): 1204-5
9. Haddad EB, Mak JCW, Barnes J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994 May; 45: 899-907
10. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002; 62 (8): 1195-203
11. Disse B, Reichl R, Speck G, et al. BA 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 1993; 52 (5-6): 537-44
12. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994 Dec; 150 (6 Pt 1): 1640-5
13. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995 Sep; 8 (9): 1506-13
14. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003 Oct; 58 (10): 855-60
15. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 Apr; 161 (4 Pt 1): 1136-42
16. O'Donnell DE, Magnussen H, Aguilanni B, et al. Spiriva (tiotropium) improves exercise tolerance in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A227
17. O'Donnell DE, Magnussen H, Aguilaniu B, et al. Spiriva (tiotropium) reduces exertional dyspnea in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A265
18. Magnussen H, O'Donnell DE, Casaburi R, et al. Spiriva® (tiotropium) reduces lung hyperinflation in COPD [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A227
19. van Noord JA, Smeets JJ, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002 Apr; 19 (4): 639-44
20. McNicholas WT, Calverley PMA, Edwards C, et al. Effects of anticholinergic therapy (tiotropium) on REM-related desaturation (SaO2) and sleep quality in patients with COPD [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A280
21. O'Donnell DE, Magnussen H, Gerken F, et al. Mechanisms of improved exercise tolerance in COPD in response to tiotropium [abstract no. P1826]. Eur Respir J 2002 Sep; 20 Suppl. 38: 288s
22. Langley S, Towse L, Kesten S, et al. Heart rate and rhythm analysis from Holter monitoring in COPD patients receiving tiotropium [abstract]. Am J Respir Crit Care Med 2002; 165 (8 Suppl. Pt 2): A592
23. Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004 May; 125 (5): 1726-34
24. O'Donnell D, Marcinuik D, Hernandez P, et al. Spiriva (tiotropium) reduces lung hyperinflation at rest and during exercise [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A772
25. O'Donnell D, Maltais F, Sciurba F, et al. Spiriva (tiotropium) improves symptom-limited exercise tolerance in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A771
26. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise endurance with the combination of tiotropium and rehabilitative exercise training in COPD patients [abstract]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A756
27. Cooper B, Kukafka D, Casaburi R, et al. Tiotropium augments improvements in dyspnea and health-related quality of life following pulmonary rehabilitation in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A518
28. Briggs Jr D, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared to salmeterol in COPD patients [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A518
29. Food and Drug Administration. Clinical pharmacology and biopharmaceutics briefing document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3890B1_06_Pharmacology-Biopharmaceutics.pdf [Accessed 2002 Sep 18]
30. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 Feb; 19 (2): 217-24
31. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. The Dutch/Belgian Tiotropium Study Group. Eur Respir J 2002 Feb; 19 (2): 209-16
32. College Ter Beoordeling Van Geneesmiddelen Medicines Evaluation Board. Public assessment report: Spiriva 18μg, inhalation powder in hard capsules RVG 26191 [online]. Available from URL: http://www.cbg-meb.nl/nl/docs/gnsmiddl/par-spiriva.pdf [Accessed 2002 Jul 23]
33. Donohue JF, Van Noord A, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002 Jul; 122 (1): 47-55
34. Van Noord JA, Aumann J, Janssens E, et al. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract no. BO24]. 99th International Conference of the American Thoracic Society; 2003 May 16-21; Seattle, (WA), A320
35. Huchon G, Verkindre C, Bart F, et al. Improvements with tiotropium on endurance measured by the shuttle walking test (SWT) and on health related quality of life (HRQoL) in COPD patients [abstract no. P1825]. Eur Respir J 2002; 20 Suppl. 38: 287s
36. O'Donnell DE, Magnussen H, Gerken F, et al. Cardiovascular evaluation of tiotropium during constant-work rate exercise in COPD [abstract no. P430]. Eur Resp J 2003; 22 Suppl. 45: 49s
37. Van Noord J, Aumann J, Jannsens E. Relation between acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPS patients [abstract no. 153]. Eur Resp J 2003 Sep; 22 Suppl. 45: 4s
38. Celli BR, ZuWallack RL, Wang S, et al. Improvements in inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124 (5): 1743-8
39. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984 Jun; 85 (6): 751-8
40. Disse B, Rominger K, Serby CW, et al. The pharmacokinetic (PK) profile of tiotropium during long-term treatment in stable COPD [abstract]. Am J Respir Crit Care Med 1999 Mar; 159 (3 Suppl. Pt 2): A524
41. Boehringer Ingelheim. Samenvatting van de productkenmerken [online]. Available from URL: http://www.cbg-meb.nl/IB-teksten/26191.PDF [Accessed 2002 Jul 24]
42. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64 (6-7): 457-64
43. Food and Drug Administration. Spiriva (tiotropium bromide inhalation powder) NDA 21-395 Boehringer Ingelheim Pharmaceuticals, Inc [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3890B1_Boehringer%20Ingelheim.pdf [Accessed 2002 Sep 18]
44. Türck D, Weber W, Sigmund R, et al. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol 2004; 44: 163-72
45. Wanner A, ZuWallack R, Elias D, et al. Efficacy of once daily tiotropium (TIO) in stable COPD [abstract no. P3406]. 9th Annual Congress of the European Respiratory Society; 1999 Oct 9-13; Madrid, (abstracts-on-disk)
46. San Pedro G, Elias DJ, Serby CW, et al. Tiotropium (Spiriva): one year bronchodilator efficacy established with once daily dosing in COPD patients [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A749
47. Zu Wallack R, Jones PW, Kotch A, et al. Tiotropium (Spiriva) improves health status in patients with COPD [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A892
48. Mahler DA, Montner P, Brazinsky SA, et al. Tiotropium (Spiriva), a new long-acting anticholinergic bronchodilator, improves dyspnea in patients with COPD [abstract]. Am J Respir Crit Care Med 2000 Mar; 161 (3 Suppl. Pt 2): A892
49. Casaburi R, Briggs Jr DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000 Nov; 118 (5): 1294-302
50. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003 May; 123 (5): 1441-9
51. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003 Sep; 97 (9): 1014-20
52. Briggs Jr DD, Witek TJ, Menjoge SS, et al. Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment [abstract no. P1589]. Eur Respir J 2002 Sep; 20 Suppl. 38: 245s
53. Hodder RV, White RJ, Menjoge SS, et al. Effectiveness of tiotropium or salmeterol in COPD patients receiving inhaled steroids [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A228
54. Friedman M, Korducki L, Kesten S. Recovery of PEFR in COPD exacerbations in one year clinical trials [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Part 2): A270
55. Spencer S, Jones PW. Decline in health status over one year is eliminated by tiotropium. Tiotropium study group [abstract]. Am J Respir Crit Care Med 2002 Apr; 165 (8 Suppl. Pt 2): A228
56. Beeh KM, Beier J, Buhl R, et al. Efficacy of tiotropium in patients with mild to moderate COPD [abstract plus poster]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A519
57. Niewoehner D, Rice K, Cote C, et al. Reduced COPD exacerbations and associated health care utilization with once-daily tiotropium (TIO) in the VA medical system [abstract]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A207
58. Friedman M, Menjoge SS, Anton S, et al. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics 2004; 22 (No. 11): 741-9
59. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003 May; 58 (5): 399-404
60. Van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000 Apr; 55 (4): 289-94
61. Vincken W, Greefhorst APM, Westbroek J, et al. Once-daily tiotropium (TIO) is more efficacious than Q.I.D. ipratropium (IB) as maintenance treatment of COPD [abstract no. P3407]. 9th Annual Congress of the European Respiratory Society; 1999 Oct 9-13; Madrid, (abstracts-on-disk)
62. de Guia T, Punzal P, Canizares L, et al. Evaluation of the response of Filipino patients to tiotropium (EVEREST Study) [abstract]. Am J Respir Crit Care Med 2004 Apr; 169 (7): A611
63. Food and Drug Administration. Clinical briefing document NDA 21-395 Spiriva (tiotropium bromide) inhalation powder for COPD [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3890B1_05_Clinical%20Briefing_%20Part%201.pdf; http://www.fda.gov/ohrms/dockets/ac/02/ briefing/3890B1_05_Clinical%20Briefing_%20Part%202.pdf [Accessed 2002 Sep 18]
64. Witek Jr TJ, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003 Mar; 56 (3): 248-55
65. Kesten S, Flanders S, Menjoge SS, et al. Improvements in COPD following treatment with tiotropium in elderly patients. Chest 2001 Oct; 120 (4 Suppl.): 163S-4S
66. Weisman I, Menjoge SS, Serby CW, et al. Influence of gender on outcomes in large COPD clinical trials [abstract]. Am J Respir Crit Care Med 2001 Apr; 163 (5 Suppl. Pt 2): A281
67. American Thoracic Society. Standardisation of spirometry: 1994 update. Am J Respir Crit Care Med 1995 Sep; 152 (3): 1107-36
68. Vincken WG, Vermiere P, Menjoge SS, et al. Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials [abstract]. Eur Respir J 2001 Sep; 18 Suppl. 33: 331s
69. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991; 85 Suppl B: 25-31
70. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992 Jun; 145 (6): 1321-7
71. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000 Feb; 117 (2 Suppl.): 54S-7S
72. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992 Jun; 30 (6): 473-83
73. Kesten S, Flanders J, Serby CW, et al. Compliance with tiotropium, a once daily dry powder inhaled bronchodilator, in one year COPD trials. Chest 2000 Oct; 118 (4 Suppl.): 191S-2S
74. Oostenbrink JB, Rutten-van Mölken MPMH, Al J, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-9
75. Boehringer Ingelheim International GmbH. Summary of product characteristics: Spiriva. Boehringer Ingelheim International GmbH, 2002
76. Boehringer Ingelheim, Pfizer Inc. Prescribing information: Spiriva® Handihaler® (tiotropium bromide inhalation powder) [online]. Available from URL: http://www.spiriva.com [Accessed 2004 Mar 12]
77. Boehringer Ingelheim, Pfizer Inc. FDA approves Spiriva Handihaler for the treatment of COPD [media release]. 2004
78. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 May; 349 (9064): 1498-504
79. National Institutes of Health: National Heart Lung and Blood Institute. Morbidity and Mortality: 2002 chart book on cardiovascular, lung, and blood diseases [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/02_chtbk.pdf [Accessed 2002 Aug 21]
80. National Center for Health Statistics. Births, marriages, divorces, and deaths for 1997. Mon Vital Stat Rep 1998 Jul 28; 46 (12): 1-18
81. National Heart Lung and Blood Institute. Data fact sheet: chronic obstructive pulmonary disease (COPD) [online]. Available from URL: http://www.nhlbi.nih.gov [Accessed 2002 Jul 15]
82. Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. Natl Vital Stat Rep 2001 Sep 21; 49 (8): 1-113
83. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2004 Mar 16]
84. Barnes PJ. Chronic obstructive pulmonary disease. N Eng J Med 2000 Jul 27; 343 (4): 269-80
85. Pauwels RA. National and international guidelines for COPD: the need for evidence. Chest 2000 Feb; 117 (2 Suppl.): 20S-2S
86. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs 2001 Apr; 10 (4): 733-40
87. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 Aug; 23 (8): 1296-310
88. Lipson DA. Redefining treatment in COPD: new directions in bronchodilator therapy. Treat Respir Med 2004; 3 (2): 89-95
89. Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996 May; 109 (5): 1163-8
90. Bauerle O, Chrusch CA, Younes M. Mechanisms by which COPD affects exercise tolerance. Am J Respir Crit Care Med 1998 Jan; 157 (1): 57-68
91. Mahler DA, Jones PW. Measurement of dyspnea and quality of life in advanced lung disease. Clin Chest Med 1997 Sep; 18 (3): 457-69
92. Jarvis B, Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drugs Aging 2001; 18 (6): 441-72
93. Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1 (4): 285-300
94. Boehringer Ingelheim, Pfizer Inc. Largest COPD outcomes study completes patient recruitment [media release]. 2004